Immutep Ltd has released a press release.
Independent DMC recommends to continue TACTI-003 as planned
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Abstracts accepted for Presentation at SITC 2022
- Fast Track granted by US FDA for Efti in 1st line NSCLC
- Immutep Receives A$2.7 million R&D French Tax Incentive
- Clinical Development Update for Eftilagimod Alpha
- New investigator-initiated ph2 trial in Soft Tissue Sarcoma
Later from Immutep
- Late Breaking Abstract accepted for SITC Oral Presentation
- New Patents Granted in Japan and South Korea for Efti
- Immutep Webcast to discuss clinical data presented at SITC
- Immutep receives A$1 million R&D Tax Incentive
- Immutep enters 2nd collaboration with Pfizer and Merck KGaA
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep